Press Releases

BIO will offer complimentary access to its proprietary BIO One-on-One Partnering™ during "JPM" week January 7-11, 2018 

California Senate Bill 17 is bad for patient and does not deliver on its purported promises

The head of the United States Food and Drug Administration, Dr. Scott Gottlieb, will be the keynote speaker at the BIO Patient and Health Advocacy Summit, October 2-3 at the Mayflower Hotel in Washington, DC. The annual event brings together…

Washington, DC (September 1, 2017) – The Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) today initiated litigation in the United States District Court for the District of Nevada…

BIO today submitted comments on EPA's proposed rule on the Renewable Fuel Standard Program: Standards for 2018 and Biomass-Based Diesel Volume for 2019.

Washington, D.C. (August 29, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement on the nomination of Andrei Iancu to lead the U.S. Patent and Trademark Office:“BIO congratulates Mr…

Enactment of FDA User Fee package important victory for patients, medical innovation

BIO announces programming for the upcoming BIO Investor Conference Oct. 17-18 in San Francisco including Kristina Burow, Managing Director of ARCH Venture Partners and Dr. Richard Scheller, Chief Science Officer & Head of Therapeutics…

Washington, DC (August 3, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S…

The U.S. Court of Appeals for the District of Columbia Circuit today supported BIO's argument that the RFS statute does not allow EPA to rely on demand-side factors under the oil industry’s control as a basis for setting annual renewable fuel…